Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia

Journal of Medicinal Chemistry

Volumn 54, Issue 14, 2011, Pages 5082-5096

  Oballa, Renata M ^a   Belair, Liette ^a   Black, W Cameron ^a   Bleasby, Kelly ^b   Chan, Chi Chung ^a   Desroches, Carole ^a   Du, Xiaobing ^b   Gordon, Robert ^a   Guay, Jocelyne ^a   Guiral, Sebastien ^a   Hafey, Michael J ^b   Hamelin, Emelie ^a   Huang, Zheng ^a   Kennedy, Brian ^a   Lachance, Nicolas ^a   Landry, France ^a   Li, Chun Sing ^a   Mancini, Joseph ^a   Normandin, Denis ^a   Pocai, Alessandro ^b   Powell, David A ^a   Ramtohul, Yeeman K ^a   Skorey, Kathryn ^a   Sørensen, Dan ^a   Sturkenboom, Wayne ^a   Styhler, Angela ^a   Waddleton, Deena M ^a   Wang, Hao ^a   Wong, Simon ^a   Xu, Lijing ^a   Zhang, Lei ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE INHIBITOR; LIPID; LUBRICATING AGENT; MF 438; MICROSOME ENZYME; MK 8245; ORGANIC ANION TRANSPORTER; OXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIDYSLIPIDEMIC ACTIVITY; ARTICLE; CELL STRAIN HEPG2; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; EXPERIMENTAL DOG; EYE; FEMALE; HARDER GLAND; HUMAN; HUMAN CELL; LIVER; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; RHESUS MONKEY; SKIN; THERAPEUTIC WINDOW;

ACETIC ACIDS; ANIMALS; CELL LINE; DIFFUSION; DOGS; FEMALE; HARDERIAN GLAND; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIVER; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; MICROSOMES; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SPECIES SPECIFICITY; STEAROYL-COA DESATURASE; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; TISSUE DISTRIBUTION;

EID: 79960632377     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200319u     Document Type: Article

References (32)

1. Ntambi, J. M.; Miyazaki, M. Regulation of stearoyl-CoA desaturases and role in metabolism Prog. Lipid Res. 2004, 43, 91-104 (Pubitemid 37487985)
2. Ntambi, J. M.; Miyazaki, M.; Stoehr, J. P.; Lan, H.; Kendziorski, C.M.; Yandell, B. S.; Song, Y.; Cohen, P.; Friedman, J. M.; Attie, A. D. Loss of stearoyl-CoA deasturase-1 function protects mice against adiposity Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11482-11486 (Pubitemid 34920951)
3. Miyazaki, M.; Kim, Y.-C.; Gray-Keller, M. P.; Attie, A. D.; Ntambi, J. M. Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat J. Biol. Chem. 2000, 275, 30132-30138
4. Miyazaki, M.; Flowers, M. T.; Sampath, H.; Chu, K.; Otzelberger, C.; Liu, X.; Ntambi, J. M. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis Cell Metab. 2007, 6, 484-496 (Pubitemid 350163054)
5. Jiang, G.; Li, Z.; Liu, F.; Ellsworth, K.; Dallas-Yang, Q.; Wu, M.; Ronan, J.; Esau, C.; Murphy, C.; Szalkowski, D.; Bergeron, R.; Doebber, T.; Zhang, B. B. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1 J. Clin. Invest. 2005, 115, 1030-1038 (Pubitemid 40489408)
6. Gutierrez-Juarez, R.; Pocai, A.; Mulas, C.; Ono, H.; Bhanot, S.; Monia, B. P.; Rossetti, L. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance J. Clin. Invest. 2006, 116, 1686-1695
7. Xu, H.; Wilcox, D.; Nguyen, P.; Voorbach, M.; Smith, H.; Brodjian, S.; Suhar, T.; Reilly, R. M.; Jacobson, P. B.; Collins, C. A.; Landschulz, K.; Surowy, T. K. Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes to fatty acid composition Front. Biosci. 2007, 12, 3781-3794
8. Li, C. S.; Belair, L.; Guay, J.; Murgasova, R.; Sturkenboom, W.; Ramtohul, Y. K.; Zhang, L.; Huang, Z. Thiazole analog as stearoyl-CoA desaturase 1 inhibitor Bioorg. Med. Chem. Lett. 2009, 19, 5214-5217
9. Leger, S.; Black, W. C.; Deschenes, D.; Dolman, S.; Falgueyret, J. P.; Gagnon, M.; Guiral, S.; Huang, Z.; Guay, J.; Leblanc, Y.; Li, C. S.; Masse, F.; Oballa, R.; Zhang, L. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438) Bioorg. Med. Chem. Lett. 2010, 20, 499-502
10. Ramtohul, Y. K.; Black, C.; Chan, C.-C.; Crane, S.; Guay, J.; Guiral, S.; Huang, Z.; Oballa, R.; Xu, L.-J.; Zhang, L.; Li, C. S. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1593-1597
11. Issandou, M.; Bouillot, A.; Brusq, J.-M.; Forest, M.-C.; Grillot, D.; Guillard, R.; Martin, S.; Michiels, C.; Sulpice, T.; Daugan, A. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models Eur. J. Pharmacol. 2009, 618, 28-36
12. Koltun, D. O.; Zilbershtein, T. M.; Migulin, V. A.; Vasilevich, N. I.; Parkhill, E. Q.; Glushkov, A. I.; McGregor, M. J.; Brunn, S. A.; Chu, N.; Hao, J.; Mollova, N.; Leung, K.; Chisholm, J. W.; Zablocki, J. Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 4070-4074
13. Attie, A. D.; Krauss, R. M.; Gray-Keller, M. P.; Brownlie, A.; Miyazaki, M.; Kastelein, J. J.; Lusis, A. J.; Stalenhoef, A. F. H.; Stoehr, J. P.; Hayden, M. R.; Ntambi, J. M. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia J. Lipid Res. 2002, 43, 1899-1907 (Pubitemid 35315808)
14. Hulver, M. W.; Berggren, J. R.; Carper, M. J.; Miyazaki, M.; Ntambi, J. M.; Hoffman, E. P.; Thyfault, J. P.; Stevens, R.; Dohm, G. L.; Houmard, J. A.; Muoio, D. M. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans Cell Metab. 2005, 2, 251-261
15. Miyazaki, M.; Man, W. C.; Ntambi, J. M. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid J. Nutr. 2001, 131, 2260-2268 (Pubitemid 32851866)
16. Kasuya, T.; Kuroda, S. Nanoparticles for human liver-specific drug and gene delivery systems: in vitro and in vivo advances Expert Opin. Drug Delivery 2009, 6, 39-52
17. Erion, M. D.; Bullough, D. A.; Lin, C.-C.; Hong, Z. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver Curr. Opin. Invest. Drugs 2006, 7, 109-117 (Pubitemid 43230906)
18. Smith, N. F.; Figg, W. D.; Sparreboom, A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination Expert Opin. Drug Metab. Toxicol. 2005, 1, 429-445
19. Girardin, M.; Alsabeh, P. G.; Lauzon, S.; Dolman, S. J.; Ouellet, S. G.; Hughes, G. The regiochemistry of the ester group in 17 was confirmed by an independent synthetic route involving the coupling of the amine component with a bromoisoxazoline intermediate Org. Lett. 2009, 11, 1159-1162
20. Joshi, V. C.; Wilson, A. C.; Wakil, S. J. Assay for the terminal enzyme of the stearoyl coenzyme A desaturase system using chick embryo liver microsomes J. Lipid Res. 1977, 18, 32-36 (Pubitemid 8031734)
21. Zhang, L.; Ramtohul, Y.; Gagné, S.; Styler, A.; Wang, H.; Guay, J.; Huang, Z. A multiplexed cell assay in HepG2 cells for the identification of delta-5, delta-6, and delta-9 desaturase and elongase inhibitors J. Biomol. Screening 2010, 15, 169-176
22. Liu, G.; Lynch, J. K.; Freeman, J.; Liu, B.; Xin, Z.; Zhao, H.; Serby, M. D.; Kym, P. R.; Suhar, T. S.; Smith, H. T.; Cao, N.; Yang, R.; Janis, R. S.; Krauser, J. A.; Cepa, S. P.; Beno, D. W. A.; Sham, H. L.; Collins, C. A.; Surowy, T. K.; Camp, H. S. Discovery of potent, selective, orally bioavailable stearoyl-CoA destaurase 1 inhibitors J. Med. Chem. 2007, 50, 3086-3100 (Pubitemid 47001252)
23. hSCD1 assay: Powell, D.; Lebrun, M.-E.; Bhat, S.; Ramtohul, Y. K. Patent WO2009/129625, 2009.
24. Volpe, D. A. Drug permeability studies in regulatory biowaiver applications Drug Absorption Stud. Biotechnol.: Pharm. Aspects 2008, 5, 665-680
25. Kirby, B. J.; Unadkat, J. D. Grapefruit juice, a glass full of drug interactions? Clin. Pharmacol. Ther. 2007, 81, 631-633 (Pubitemid 46625123)
26. Other OATP substrates such as statins have been shown to have intestinal absorption by OATPs: Shirasaka, Y.; Suzuki, K.; Nakanishi, T.; Tamai, I. Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide Pharm. Res. 2010, 27, 2141-2149
27. Bleasby, K.; Castle, J. C.; Roberts, C. J.; Cheng, C.; Bailey, W. J.; Sina, J. F.; Kulkarni, A. V.; Hafey, M. J.; Evers, R.; Johnson, J. M.; Ulrich, R. G.; Slatter, J. G. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition Xenobiotica 2006, 36, 963-988 (Pubitemid 44844110)
28. Konig, J.; Cui, Y.; Nies, A. T.; Keppler, D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278, G156-164
29. Lan, R.; Liu, Q.; Fan, P.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists J. Med. Chem. 1999, 42, 769-776 (Pubitemid 29110792)
30. Talber, R. L. Safety issues with statin therapy J. Am. Pharm. Assoc. 2003, 46, 479-488
31. Niemi, M. Role of OATP transporters in the disposition of drugs Pharmacogenomics 2007, 8, 787-802 (Pubitemid 47288978)
32. SEARCH Collaborative Group. SLCO1B1 Variants and statin-induced myopathy-a genomewide study N. Engl. J. Med. 2008, 359, 789-799